{"title":"多奈单抗治疗早期症状阿尔茨海默病","authors":"BMJ Publishing Group Ltd","doi":"10.1136/dtb.2024.000020","DOIUrl":null,"url":null,"abstract":"### Key learning points The authors of a phase 3 trial involving people with early Alzheimer’s disease (AD) reported that although donanemab produced a small reduction in clinical progression compared with placebo, it was associated with some serious adverse effects.1 The TRAILBLAZER-ALZ 2 trial was a 76-week, phase 3, randomised, double-blind, placebo-controlled study that recruited participants aged 60–85 years with early symptomatic AD, a Mini-Mental State Examination score of 20–28 and confirmed amyloid and tau pathology assessed by positron emission tomography (PET) scans.1 A total of 1736 …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"65 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Donanemab in early symptomatic Alzheimer’s disease\",\"authors\":\"BMJ Publishing Group Ltd\",\"doi\":\"10.1136/dtb.2024.000020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"### Key learning points The authors of a phase 3 trial involving people with early Alzheimer’s disease (AD) reported that although donanemab produced a small reduction in clinical progression compared with placebo, it was associated with some serious adverse effects.1 The TRAILBLAZER-ALZ 2 trial was a 76-week, phase 3, randomised, double-blind, placebo-controlled study that recruited participants aged 60–85 years with early symptomatic AD, a Mini-Mental State Examination score of 20–28 and confirmed amyloid and tau pathology assessed by positron emission tomography (PET) scans.1 A total of 1736 …\",\"PeriodicalId\":11277,\"journal\":{\"name\":\"Drug and Therapeutics Bulletin\",\"volume\":\"65 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug and Therapeutics Bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/dtb.2024.000020\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and Therapeutics Bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/dtb.2024.000020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Donanemab in early symptomatic Alzheimer’s disease
### Key learning points The authors of a phase 3 trial involving people with early Alzheimer’s disease (AD) reported that although donanemab produced a small reduction in clinical progression compared with placebo, it was associated with some serious adverse effects.1 The TRAILBLAZER-ALZ 2 trial was a 76-week, phase 3, randomised, double-blind, placebo-controlled study that recruited participants aged 60–85 years with early symptomatic AD, a Mini-Mental State Examination score of 20–28 and confirmed amyloid and tau pathology assessed by positron emission tomography (PET) scans.1 A total of 1736 …
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
